1. Home
  2. ZTS

as 05-20-2024 4:00pm EST

$
-
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Founded: 1952 Country:
United States
United States
Employees: N/A City: PARSIPPANY
Market Cap: 79.1B IPO Year: 2013
Target Price: $211.57 AVG Volume (30 days): 3.7M
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield: 0.99% Dividend Payout Frequency: Quarterly
EPS: 5.19 EPS Growth: 17.42
52 Week Low/High: $144.80 - $201.92 Next Earning Date: 05-02-2024
Revenue: $8,734,000,000 Revenue Growth: 7.91%
Revenue Growth (this year): 8.6% Revenue Growth (next year): 7.10%

Share on Social Networks:

Stock Insider Trading Activity of Zoetis Inc. (ZTS)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Lagano Roxanne ZTS Executive Vice President Apr 18 '24 Sell $151.17 923 $139,529.91 14,800 SEC Form 4
Reed Willie M ZTS Director Mar 11 '24 Sell $182.68 1,370 $250,264.75 9,994 SEC Form 4
PECK KRISTIN C ZTS Chief Executive Officer Feb 20 '24 Sell $187.20 13,000 $2,433,636.40 79,366 SEC Form 4
Lagano Roxanne ZTS Executive Vice President Jan 18 '24 Sell $191.43 923 $176,689.89 17,569 SEC Form 4
Lagano Roxanne ZTS Executive Vice President Dec 14 '23 Sell $200.00 2,500 $500,000.00 19,415 SEC Form 4